title: Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS.
abstract: The effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration on the functional status of polymorphonuclear leukocytes (PMNL) in neutropenic AIDS patients was investigated. PMNL destructive activity against Candida albicans or encapsulated or acapsular Cryptococcus neoformans was significantly impaired with respect to control subjects before rhG-CSF treatment. After subcutaneous administration of rhG-CSF (5 micrograms/kg), neutrophil counts increased 3- to 11-fold in 24 h and returned to baseline within 96 h. PMNL fungicidal activity showed significant enhancement 48-72 h after rhG-CSF administration that decreased to baseline within 96 h. Enhanced rhG-CSF-mediated destructive activity strictly correlated with augmented superoxide anion production by PMNL. These findings suggest that therapeutic use of rhG-CSF at appropriate schedules in neutropenic AIDS patients could decrease the risk of infection or, in association with antibiotic therapy, more rapidly resolve the occurring infections.
authors.affiliation: Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Vecchiarelli
authors.forename: C
authors.initials: C
authors.lastname: Monari
authors.forename: F
authors.initials: F
authors.lastname: Baldelli
authors.forename: D
authors.initials: D
authors.lastname: Pietrella
authors.forename: C
authors.initials: C
authors.lastname: Retini
authors.forename: C
authors.initials: C
authors.lastname: Tascini
authors.forename: D
authors.initials: D
authors.lastname: Francisci
authors.forename: F
authors.initials: F
authors.lastname: Bistoni
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D000328:Adult; D002176:Candida albicans / Q000276:immunology; D003455:Cryptococcus neoformans / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007111:Immunity, Cellular; D009181:Mycoses / Q000150:complications / Q000276:immunology*; D009503:Neutropenia / Q000150:complications; D009504:Neutrophils / Q000276:immunology*; D010587:Phagocytosis / Q000187:drug effects; D011994:Recombinant Proteins; D016897:Respiratory Burst / Q000187:drug effects; D013481:Superoxides / Q000378:metabolism
chemical_list: D011994:Recombinant Proteins; D013481:Superoxides; D016179:Granulocyte Colony-Stimulating Factor